Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives
ReviewHumans
- Design
- Review
- Subjects
- Commentary
- Dose used in the study
- Not applicable
- Duration
- Not applicable
- What was measured
- A critique of a 2014 review (Skaper and colleagues) that claimed superiority for micronised and ultramicronised formulations
What the authors reported
The author says the reviewed paper does not meet the minimum condition for its superiority claim: a comparison of pure palmitoylethanolamide (or other formulations) against micronised and ultramicronised forms. At least two authors of the reviewed paper have direct connections to Epitech and Innovet. He argues for pure palmitoylethanolamide without additives until that comparison is done.
Limits of this study
A commentary, not data. Its central point is that the reviewed paper did not make the comparison needed to support a superiority claim. The author is listed at JP Rusell Science Ltd, Nicosia, Cyprus.
Source
PubMed 24647619 · doi:10.1007/s10787-014-0202-3
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.